Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biomedical Research

This article was originally published in SRA

Executive Summary

Government starts consultation on privacy rights in Singapore

You may also be interested in...



J&J Helping Out Vulnerable Children With UK Calpol Campaign

In a recent PR campaign for Calpol in the UK, Johnson & Johnson Consumer Health partnered with children’s charity NSPCC to raise awareness of the latter's helpline. HBW Insight speaks exclusively to J&J's head of Marketing for Northern Europe at J&J Consumer Health, Hannah French.

EMA Stands By Suspension Of Ranitidine

Suspension of heartburn remedy ranitidine looming in the EU as the European Medicines Agency stands by its original decision.

Sun’s Indian Nilotinib Plans Blocked By Novartis

Novartis thwarts Sun’s efforts to commercialize nilotinib in India, though the Indian firm indicates that its actions are covered under a local Bolar-type provision and that it has no plans to market the oncology drug while the originator's patent stands valid.

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel